Vera Therapeutics, Inc. (VERA) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-86.6%

$4.05

vs $30.25 price

Levered DCF

$4.32

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

6.48

Safe zone

Rating

C-

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	-10.87×	-15.38×	-6.84×	-5.78×	-11×	-0.8×	-3.32×
P/B	5.38×	4.05×	6.46×	6.69×	5.16×	-0.48×	-1.08×
P/S	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-10.2×	-15.94×	-7.21×	-5.65×	-8.77×	0.21×	-3.21×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	13.64×	25.67×	7.71×	4.91×	10.73×	22.55×	3.36×
Debt / equity	0.13×	0.09×	0.53×	0.41×	0.07×	-0×	-0×
Interest coverage	-41.89×	-21.92×	-26.94×	-91.64×	-1,720.1×	-289.52×	-234.53×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	-49.6%	-26.4%	-94.4%	-115.8%	-46.9%	59.8%	32.4%
Return on invested capital	-46.3%	-26.5%	-65.5%	-83.8%	-45.2%	-92.2%	-269.2%
Return on assets	-40.8%	-23.2%	-54.7%	-67.8%	-38.9%	-97.9%	-220.3%
Free cash flow yield	-7.4%	-5.8%	-14.0%	-13.2%	-6.6%	-81.9%	-26.5%
Earnings yield	-9.2%	-6.5%	-14.6%	-17.3%	-9.1%	-125.3%	-30.1%
Enterprise value	$3B	$2.3B	$664.9M	$502M	$284.3M	-$11M	$36.3M
Net debt / EBITDA	0.95×	0.26×	-0.09×	0.14×	2.31×	1.01×	0.27×
Cash conversion cycle (days)	0	0	0	5,173	0	-1,322	-245